Sandoz Articles
Novartis set to reintegrate Sandoz generics unit
22 November 2004
Sandoz' Omnitrope OKed in Australia
11 October 2004
Bushu's revival under Shionogi umbrella
11 October 2004
FDA defers decision on Sandoz' application for Omnitrope
13 September 2004
Novartis completes Sabex acquisition
23 August 2004
Experts warn on levothyroxine potency differences
16 August 2004
AstraZeneca's 2nd-qtr sales jump 19%
2 August 2004
Lek opens production plant in Romania
12 July 2004
Stock Commentary - New York
5 July 2004
Sandoz acquires Denmark's Durascan
5 July 2004
Letter from the Editor
21 June 2004
Novartis to invest in Polish generics
24 May 2004
Sandoz launches generic Rebetol
12 April 2004
Blending of branded and generic pharma: a rising trend?
12 April 2004
Confusion in EU biogenerics sector
5 April 2004
Vasella outlines Lek's lead role at Sandoz
15 March 2004
Novartis' Slovenian subsidiary Lek boosts biopharma activity
23 February 2004
Spanish antibiotics firm for Novartis
9 February 2004
Novartis acquires new Spanish capacity
15 December 2003
Novartis' Sandoz branding reaches US
8 December 2003
Novartis' sales on track in third quarter; profits rise 7% as Diovan, Gleevec deliver
27 October 2003
Novartis to rebrand generics under single global name: Sandoz
27 January 2003
Stock Commentary - Europe
15 April 2002
Sandoz Family sells quarter of stake in Novartis
15 April 2002
Novartis sees launch of cancer drug by 2001
18 April 2000
"Rising tide" of pharma consolidation reviewed by banker
21 October 1999
Novartis looking to cut costs in Switzerland
11 August 1999
US appeal court rejects price-fixing claims
20 July 1999
Novartis fined $27.5 million in Japan
3 March 1999
Drug majors settle pricing lawsuit in USA
22 February 1999
Drug Majors Lose Competition Lawsuit
7 December 1998
Roche, Lilly Close Venezuela Facilities
2 November 1998
Novartis Restructures After Disappointing First Half
1 September 1998
Parke-Davis Heads Rankings In Pakistan
17 August 1998
Multinationals In Japan Slim Down Faster Than Locals
14 July 1998
Novartis India Expands Product Range
8 July 1998
UK Health Care Exports To North Africa
29 June 1998
Modest Sales Growth At Novartis Worries Market
17 June 1998
AHP & Monsanto Merger Creates $96 Billion Firm
4 June 1998
Pharma Industry Consolidation Accelerating
3 June 1998
AHP & Monsanto Merger Creates $96 Billion Firm
2 June 1998
First Operational Year Strong At Novartis
19 March 1998
GW-SB Merger Will Create R&D Superpower
5 February 1998
DTC Ads On Television Effectiveness Studied
30 December 1998
French Reimbursable Delistings
18 December 1997
New Advances In The Treatment Of Sepsis?
9 October 1997
Mental Health Study Slams Managed Care
24 September 1997
UK Industry Code Of Practice Report
1 September 1997
Local Firms Raise Share Of Middle East Drug Tender
1 September 1997
Strong Advance In 1st-Half Profits At Novartis
29 August 1997
Weak Earnings At BASF; Health Sales Up
20 August 1997
East European Pharma Moves Ahead Of EU Entry
1 July 1997
Outlook Favorable For Global Health Care
23 June 1997
Diovan "More Efficacious" Than Cozaar, New Data
9 June 1997
Roche Buys Corange In Major Diagnostics Move
30 May 1997
Cortecs' Oral Calcitonin Shows Early Promise
19 May 1997
Novartis to Acquire Merck Business
19 May 1997
Novartis Ousts GW As Top Drug Firm
9 April 1997
Bid To Change California Mental Illness Drug Policy
9 April 1997
1996 A Demanding Year For Novartis
19 March 1997
Pharma Strategies: M&A Or Technical Excellence?
3 March 1997
Sales Advance 8% In 1996 At Novartis
3 February 1997
Eisai's Aricept Available In USA, Its First Market
27 January 1997
UK Rx Medicines Code Of Practice Report
20 January 1997
Zocor "Will Be World's Top-Selling Drug In 2005"
13 January 1997
AIG To Invest $5.1m In Novartis Unit
13 January 1997
EUROPEAN AND LONDON STOCK COMMENT
13 January 1997
SangStat's Ciclosporin "Bioequivalent" To Neoral
13 January 1997
Acquisitions And Mergers Continue, Led By Novartis
6 January 1997
FDA Year-End Approval Spate As Expected
6 January 1997
No Hidden Surprises From US FTC For Birth Of Novartis
6 January 1997
EUROPEAN STOCK COMMENT
23 December 1996
Novartis Gets Go-Ahead From US FTC
23 December 1996
New Over-The-Counter League From IMS
23 December 1996
Product News In 1996 Dominated By CNS
23 December 1996
Sandoz Sells MBT Division
9 December 1996
Atorvastatin: 1st Approvals In UK And Germany
9 December 1996
Stock Commentary: Europe
9 December 1996
FDA Approves Elan's Zanaflex For Spasticity
9 December 1996
SangStat Files For US Ciclosporin Approval
9 December 1996
Dutch Government Reimbursement Blacklist Rises To 35
9 December 1996
Sandoz' Alzheimer's Drug; International Data Revealed
2 December 1996
Boeh Mannheim Starts Anti-HBV Trials
2 December 1996
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- US Supreme Court says patent settlement can "sometimes" be illegal
- Negative US patent ruling for Novo Nordisk on Prandin
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
